Search Results - "Saw, R P"

Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma by Rozeman, E. A., Hoefsmit, E. P., Reijers, I. L. M., Saw, R. P. M., Versluis, J. M., Krijgsman, O., Dimitriadis, P., Sikorska, K., van de Wiel, B. A., Eriksson, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L. G., Shannon, K., Haanen, J. B. A. G., Stretch, J., Ch’ng, S., Nieweg, O. E., Mallo, H. A., Adriaansz, S., Kerkhoven, R. M., Cornelissen, S., Broeks, A., Klop, W. M. C., Zuur, C. L., van Houdt, W. J., Peeper, D. S., Spillane, A. J., van Akkooi, A. C. J., Scolyer, R. A., Schumacher, T. N. M., Menzies, A. M., Long, G. V., Blank, C. U.

“…Neoadjuvant ipilimumab plus nivolumab showed high pathologic response rates (pRRs) in patients with macroscopic stage III melanoma in the phase 1b OpACIN (…”
Get full text

Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial by Lee, T. S., Li, I., Peric, B., Saw, R. P. M., Duprat, J. P., Bertolli, E., Spillane, J. B., van Leeuwen, B. L., Moncrieff, M., Sommariva, A., Allan, C. P., de Wilt, J. H. W., Jones, R. Pritchard, Geh, J. L. C., Howle, J. R., Spillane, A. J.

“…Background The Evaluation of Groin Lymphadenectomy Extent for Melanoma (EAGLE FM) study sought to address the question of whether to perform inguinal (IL) or…”
Get full text

ASO Visual Abstract: Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective Randomized Trial by Lee, T. S., Li, I., Peric, B., Saw, R. P. M., Duprat, J. P., Bertolli, E., Spillane, J. B., van Leeuwen, B. L., Moncrieff, M., Sommariva, A., Allan, C., de Wilt, J. H. W., Pritchard-Jones, R., Geh, J. L. C., Howle, J. R., Spillane, A. J.

Get full text

Cutaneous sarcoidosis due to immune‐checkpoint inhibition and exacerbated by a novel BRAF dimerization inhibitor by Pham, J. P., Star, P., Wong, S., Damian, D. L., Saw, R. P. M., Whitfeld, M. J., Menzies, A. M., Joshua, A. M., Smith, A.

“…Sarcoidosis is a non‐infective granulomatous disorder of unknown aetiology, with cutaneous involvement affecting up to 30% of patients. Drug‐induced…”
Get full text

The Management of Cervical Lymph Nodes in Patients with Cutaneous Melanoma by Martin, R. C. W., Shannon, K. F., Quinn, M. J., Saw, R. P. M., Spillane, A. J., Stretch, J. R., Colman, M. H., Gao, K., Thompson, J. F.

“…Background The aim of this study was to review the management of cervical lymph nodes in patients with cutaneous melanoma and to analyze factors influencing…”
Get full text

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients by Lee, J.H., Saw, R.P., Thompson, J.F., Lo, S., Spillane, A.J., Shannon, K.F., Stretch, J.R., Howle, J., Menzies, A.M., Carlino, M.S., Kefford, R.F., Long, G.V., Scolyer, R.A., Rizos, H.

“…The outcomes of patients with stage III cutaneous melanoma who undergo complete surgical resection can be highly variable, and estimation of individual risk of…”
Get full text

Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma by Tetzlaff, M.T., Messina, J.L., Stein, J.E., Xu, X., Amaria, R.N., Blank, C.U., van de Wiel, B.A., Ferguson, P.M., Rawson, R.V., Ross, M.I., Spillane, A.J., Gershenwald, J.E., Saw, R.P.M., van Akkooi, A.C.J., van Houdt, W.J., Mitchell, T.C., Menzies, A.M., Long, G.V., Wargo, J.A., Davies, M.A., Prieto, V.G., Taube, J.M., Scolyer, R.A.

“…Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To…”
Get full text

Same‐day or next‐day sentinel node biopsy after lymphoscintigraphy for melanoma using 99mTc‐labelled antimony sulphide colloid by Thompson, J. F., London, K., Uren, R. F., Pennington, T. E., Saw, R. P. M., Lo, S. N.

“…Background Two recent publications have reported that a shorter interval between preoperative lymphoscintigraphy and sentinel node biopsy (SNB) is associated…”
Get full text

Five-year analysis of neoadjuvant dabrafenib and trametinib for stage III melanoma by Menzies, A M, Lo, S N, Saw, R P M, Gonzalez, M, Ch'ng, S, Nieweg, O E, Shannon, K F, Ferguson, P M, Lee, J, Emmett, L, Kapoor, R, Rawson, R V, Stretch, J R, Thompson, J F, Spillane, A J, Rizos, H, Scolyer, R A, Long, G V

“…Neoadjuvant dabrafenib plus trametinib has a high pathological response rate and impressive short-term survival in patients with resectable stage III melanoma…”
Get more information

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma by Tetzlaff, M.T., Adhikari, C., Lo, S., Rawson, R.V., Amaria, R.N., Menzies, A.M., Wilmott, J.S., Ferguson, P.M., Ross, M.I., Spillane, A.J., Vu, K.A., Ma, J., Ning, J., Haydu, L.E., Saw, R.P.M., Wargo, J.A., Tawbi, H.A., Gershenwald, J.E., Long, G.V., Davies, M.A., Scolyer, R.A.

“…Recent clinical trials demonstrated the safety and efficacy of neoadjuvant dabrafenib and trametinib (DT) among patients with surgically resectable clinical…”
Get full text

Understanding quality of life issues in patients with advanced melanoma: Phase 1 and 2 in the development of the EORTC advanced melanoma module by Egeler, M.D., van Leeuwen, M., Lai-Kwon, J., Eriksson, H., Bartula, I., Elashwah, S., Fox, L., Van Hemelrijck, M., Jefford, M., Lijnsvelt, J., Bagge, A.-S. Lindqvist, Morag, O., Ny, L., Bagge, R. Olofsson, Rogiers, A., Saw, R.P.M., Serpentini, S., Iannopollo, L., Thompson, J., Stiller, H. Tufvesson, Vanlaer, N., van Akkooi, A.C.J., van de Poll-Franse, L.V.

“…We aimed to develop a European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) module tailored for patients with advanced…”
Get full text

Reflectance confocal microscopy – a non‐invasive tool for monitoring systemic treatment response in stage III unresectable primary scalp melanoma by Ho, G., Schwartz, R.J., Regio Pereira, A., Dimitrou, F., Paver, E., McKenzie, C., Saw, R.P.M., Scolyer, R.A., Long, G.V., Guitera, P.

Get full text

Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management by Rawson, R.V., Vergara, I.A., Stretch, J.R., Saw, R.P.M., Thompson, J.F., Lo, S.N., Scolyer, R.A., Busam, K.J.

“…Desmoplastic melanoma (DM) is an uncommon subtype of melanoma with distinct clinicopathological features. It is classified into pure desmoplastic melanoma…”
Get full text

p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer by Saw, R. P. M., Koorey, D., Painter, D., Gallagher, P. J., Solomon, M. J.

“…Background: Hepatic metastasis from colorectal cancer is a common problem. Hepatic resection offers the only chance of cure. Prognosis of patients following…”
Get full text

Melanoma patient imaging in the era of effective systemic therapies by Stodell, M, Thompson, J.F, Emmett, L, Uren, R.F, Kapoor, R, Saw, R.P.M

“…Abstract Imaging plays a critical role in the current multi-disciplinary management of patients with melanoma. It is used for primary disease staging, surgical…”
Get full text

Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre by Read, R.L, Pasquali, S, Haydu, L, Thompson, J.F, Stretch, J.R, Saw, R.P.M, Quinn, M.J, Shannon, K, Spillane, A.J

“…Abstract Background The quality of melanoma surgery needs to be assessed by oncological outcome and complication rates. There is no published consensus on…”
Get full text

Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials by Versluis, J.M., Menzies, A.M., Sikorska, K., Rozeman, E.A., Saw, R.P.M., van Houdt, W.J., Eriksson, H., Klop, W.M.C., Ch’ng, S., van Thienen, J.V., Mallo, H., Gonzalez, M., Torres Acosta, A., Grijpink-Ongering, L.G., van der Wal, A., Bruining, A., van de Wiel, B.A., Scolyer, R.A., Haanen, J.B.A.G., Schumacher, T.N., van Akkooi, A.C.J., Long, G.V., Blank, C.U.

“…Neoadjuvant ipilimumab plus nivolumab has yielded high response rates in patients with macroscopic stage III melanoma. These response rates translated to high…”
Get full text

Pathological response and tumour bed histopathological features correlate with survival following neoadjuvant immunotherapy in stage III melanoma by Rawson, R.V., Adhikari, C., Bierman, C., Lo, S.N., Shklovskaya, E., Rozeman, E.A., Menzies, A.M., van Akkooi, A.C.J., Shannon, K.F., Gonzalez, M., Guminski, A.D., Tetzlaff, M.T., Stretch, J.R., Eriksson, H., van Thienen, J.V., Wouters, M.W., Haanen, J.B.A.G., Klop, W.M.C., Zuur, C.L., van Houdt, W.J., Nieweg, O.E., Ch'ng, S., Rizos, H., Saw, R.P.M., Spillane, A.J., Wilmott, J.S., Blank, C.U., Long, G.V., van de Wiel, B.A., Scolyer, R.A.

“…Guidelines for pathological evaluation of neoadjuvant specimens and pathological response categories have been developed by the International Neoadjuvant…”
Get full text

1905PAdvanced melanoma patients with high CD16+ macrophages have better response and survival to anti-PD-1 based immunotherapy by Lee, H, Silva, I D, Batten, M, Palendira, U, Ferguson, A, Carlino, M S, Menzies, A M, Saw, R P, Spillane, A J, Scolyer, R A, Long, G V, Wilmott, J

“…Abstract Background Anti-PD-1 and anti-CTLA-4 immunotherapies have become the standard of care for metastatic melanoma. However, the majority of patients…”
Get full text

LBA7518-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma by Rozeman, E A, Menzies, A M, Krijgsman, O, Hoefsmit, E P, van de Wiel, B A, Sikorska, K, Van, T M, Eriksson, H, Bierman, C, Gonzalez, M, Shannon, K, Broeks, A, Kerkhoven, R, Spillane, A J, Saw, R P, van Akkooi, A C J, Scolyer, R A, Hansson, J, Long, G V, Blank, C U

“…Abstract Background Primary analysis of the OpACIN-neo study testing 3 dosing schedules of neoadj IPI+NIVO identified 2 cycles IPI 1 mg/kg + NIVO 3 mg/kg…”
Get full text